Genomic alterations in thyroid cancer: biological and clinical insights

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Thyroid tumours originate from follicular cells acquiring driver mutations.
• Constitutive activation of the MAPK signalling pathway is a key event in thyroid tumour initiation.
• Additional mutations in specific genes promote tumour progression, leading to aggressive and less differentiated disease.

Purpose of the Study:

• To review the biological basis of genetic alterations in thyroid cancer initiation and progression.
• To discuss the implementation of genomic information for improved thyroid cancer management.
• To explore strategies for patient stratification, prognosis, redifferentiation, and targeted therapies.

Main Methods:

• Analysis of thyroid tumour sequencing data from patients.
• Identification of mutation-specific mechanisms through experimental models.
• Review of current literature on thyroid cancer genetics and targeted therapies.

Main Results:

• Thyroid cancer's genomic simplicity facilitates unprecedented insights into its biology.
• Driver mutations activating the MAPK pathway are crucial for tumour initiation.
• A limited set of additional mutations dictates tumour aggressiveness and differentiation status.

Conclusions:

• Genomic insights are transforming thyroid cancer management, leading to refined stratification and treatment strategies.
• Understanding genetic alterations is essential for developing effective targeted therapies and improving patient prognosis.
• Translating genomic knowledge into clinical practice holds significant promise for advancing thyroid cancer care.